The Pharma Data

OCTOBER 21, 2020

headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immuno-gene therapies for the treatment of cancer. About Replimune Replimune Group, Inc.,

Immune Response 40

Immune Response Clinical Trials Production Therapies 40

Drug Discovery World

MAY 11, 2023

Gene-based therapeutics and vaccines hold immense potential for more efficient and personalised treatment and prevention of complex diseases. Another dangerous consequence can occur when the therapeutic or vaccine introduces proteins that can activate an uncontrolled immune response. 2015): 1727-1737. Collins, Ben C.,

Production 130

Production Vaccine Immune Response Therapies 130

The Pharma Data

MARCH 29, 2022

Application based on CheckMate -816, the only Phase 3 trial to demonstrate improved event-free survival and pathologic complete response with an immunotherapy-based combination in the neoadjuvant setting of NSCLC. Opdivo -based treatments have shown clinical benefit in four Phase 3 trials in earlier stages of cancer.

Treatment 52

Treatment Clinical Trials Trials Immune Response 52

The Pharma Data

APRIL 16, 2021

Approval based on Phase 3 CheckMate -9ER trial results showing Opdivo in combination with Cabometyx significantly improved overall survival and doubled median progression-free survival and objective response rates compared to sunitinib. vice president, development program lead, genitourinary cancers, Bristol Myers Squibb.

Treatment 52

Treatment Trials Clinical Trials Immune Response 52

The Pharma Data

AUGUST 17, 2021

In the Opdivo plus Yervoy arm, patients received treatment with Opdivo 3 mg/kg every 2 weeks and Yervoy 1 mg/kg every 6 weeks up to 24 months or until disease progression or unacceptable toxicity. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

JULY 21, 2021

Pfizer and Biovac have worked together since 2015 on the sterile formulation, fill, finish and distribution of the Prevenar 13 vaccine. Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 15 ISACs use small immuno-agonist molecules conjugated to the antibody to boost the immune response while minimising toxicity.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Cell Biology Clinical Trials Trials 118

Drug Discovery World

JULY 31, 2023

Personalised medicine therapies, such as immunotherapies for cancers that are challenging to treat, are designed to elicit a patient’s own immune response to identify and destroy cancer cells and prevent recurrence. The speed, accuracy, and cost of DNA manufacturing need to be addressed to enable personalised medicine.

DNA 130

DNA Vaccine Therapies Production 130

The Pharma Data

SEPTEMBER 8, 2021

Phase 3 data from RELATIVITY-047 demonstrate prolonged benefit beyond initial treatment of the LAG-3 blocking antibody relatlimab and PD-1 inhibitor nivolumab fixed-dose combination for patients with previously untreated unresectable or metastatic melanoma. Summary of Presentations. All times noted are Central European Summer Time (CEST).

Research 52

Research Immune Response Treatment Trials 52

The Pharma Data

OCTOBER 28, 2020

We are pursuing an accelerated approval pathway for remestemcel-L in the treatment of children with SR-aGVHD, and a parallel approval pathway for COVID-19 ARDS if the randomized controlled Phase 3 trial is positive.”. agents and even among responders, up to 10% will lose their response to the drug every year.

Treatment 40

Treatment Trials Production Disease 40

The Pharma Data

JUNE 30, 2021

The EC’s decision is based on results from the Phase 2 CheckMate -142 trial in which Opdivo plus Yervoy demonstrated a clinically meaningful improvement in objective response rate (ORR) in patients with MSI-H/dMMR mCRC who received prior treatment with fluoropyridine, oxaliplatin and irinotecan. achieving a complete response.

Treatment 52

Treatment Trials FDA Approval Disease 52

The Pharma Data

APRIL 9, 2021

today announced positive topline results from the Phase 3 CheckMate -648 trial evaluating treatment with Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab ) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC).

Clinical Trials 52

Clinical Trials Trials Immune Response Treatment 52

Drug Discovery World

FEBRUARY 15, 2023

Cancer is a complex heterogenous multistep disease characterised by uncontrolled cell proliferation combined with a dysregulated immune response. A healthy immune system is naturally primed to eliminate malignant and abnormal cells through a synchronised and dynamic interplay between adaptive and innate immunity.

Research 130

Research Therapies Immune Response Clinical Trials 130

Codon

AUGUST 27, 2024

For example, many different filoviruses attack white blood cells and cause similar innate immune responses , which makes it difficult to identify a particular species from only their DNA. Putting a sequencer in every port, hospital, water treatment plant, or subway station isn’t feasible just yet due to the expense.

DNA 84

DNA Hospitals Laboratories Virus 84

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. Many patients with severe asthma have an inadequate response to currently available biologics and oral corticosteroids and thus fail to achieve asthma control.(2,6,9)

FDA 52

FDA Trials Therapies Treatment 52

The Pharma Data

APRIL 11, 2021

today announced results from the CheckMate -816 study, which showed that neoadjuvant treatment with three cycles of Opdivo (nivolumab) plus chemotherapy significantly improved pathologic complete response (pCR), a primary endpoint, compared to chemotherapy alone in patients with resectable stage Ib to IIIa non-small cell lung cancer (NSCLC).

Trials 52

Trials Treatment Immune Response Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

We look forward to engaging health authorities worldwide with the goal of bringing this immunotherapy-based treatment option to patients as soon as possible.”. All patients continued treatment for two years or until disease progression, unacceptable toxicity or withdrawal of consent. Waxman, M.D., About Esophageal Cancer.

Treatment 52

Treatment Trials Therapies Clinical Trials 52

The Pharma Data

MARCH 31, 2023

Grade 3-4 treatment-related and surgery-related adverse events occurred in 36% and 11% of patients in the Opdivo with chemotherapy arm, respectively, vs. 38% and 15% in the chemotherapy arm, respectively. “The With median follow up of 41.4 vice president, thoracic cancers development lead, Bristol Myers Squibb. “At

Trials 40

Trials Clinical Trials Treatment Immune Response 40

The Pharma Data

JUNE 18, 2021

PREVNAR 20 is a vaccine indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in adults 18 years of age and older. during 2015-2016. IMPORTANT SAFETY INFORMATION.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

NOVEMBER 9, 2020

Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma. Severe Asthma in Adults. Am J Respir Crit Care Med.

Trials 52

Trials Production Clinical Trials Government 52

The Pharma Data

MARCH 11, 2021

In HCC, despite evolution of the treatment landscape over the past few years, we believe Opdivo continues to address an unmet medical need for patients in the post-sorafenib setting, and we appreciate the opportunity to discuss this in more depth with the Committee.”. Waxman, M.D.,

Treatment 52

Treatment Trials Therapies FDA Approval 52

Drug Discovery World

SEPTEMBER 29, 2022

While there are steps that individuals can take to reduce their risk of contracting CMV, there are no existing treatments or preventative vaccines to address CMV transmission, the subsequent infection or the longer-term manifestations of infection. Progression of vaccines . The potential future of mRNA in CMV prevention .

Vaccine 130

Vaccine Immune Response Virus Disease 130

The Pharma Data

AUGUST 11, 2020

In the trial, treatment with Opdivo following neoadjuvant chemoradiation therapy (CRT) and complete surgical resection demonstrated a statistically significant improvement in the primary endpoint of DFS compared to placebo in the all-randomized population. MBA, Director of the Charles A.

Therapies 52

Therapies Trials Disease Treatment 52

SugarCone Biotech

MAY 28, 2019

These efforts can be traced back to the approval of high dose IL-2 for the treatment of renal cell carcinoma in 1992 and metastatic melanoma in 1998. Jounce Therapeutics and Immune-Onc showed preclinical data at SITC 2020 on their anti-LILBR2 (ILT-4) programs, and there are additional efforts underway. Fc-hacking immune responses.

Immune Response 52

Immune Response Therapies Engineering Regulations 52